Schizophrenia - Biotech, Pharma and Life Science Channel
Schizophrenia is a common serious long-term mental health condition that affects 5 in 1000 in the UK. It causes a range of different psychological symptoms; hallucinations, delusions, muddled thoughts based on the hallucinations or delusions and changes in behavior. When these ideas can not be separated from reality, schizophrenia is termed a psychotic illness. It does not causes patients to develop a split personality or become violent.
There may be genetic and environmental factors associated with developing schizophrenia; an association with drugs abuse is also being tested. The onset of the condition is in late teenage years and early adulthood (slightly later in females).
There is no known cause or cure. Treatment involves antipsychotic medications as well and psychological therapy and provision of a supportive environment.
Source; Adapted from NHS
Add the Schizophrenia News Channel to your RSS reader;
Follow the Schizophrenia Twitter feed;
PubMed Articles
Schizophrenia - a disorder in its own right? : Results from 25 years of the ABC study.
BACKGROUND: The ABC schizophrenia study conducted by the same team over 25 years initially aimed at illuminating the onset, prodromal stage and sex differences in age at first hospitalization in schiz...
BACKGROUND: We compared the time to discontinuation due to lack of tolerability over 24 weeks in patients suffering from schizophrenia treated with pomaglumetad methionil (LY2140023 monohydrate, the p...
This retrospective cohort study examined rates of conformance to continuity of care treatment guidelines and factors associated with conformance for persons with schizophrenia. Subjects were 8,621 adu...
High rate of disease-related copy number variations in childhood onset schizophrenia.
Copy number variants (CNVs) are risk factors in neurodevelopmental disorders, including autism, epilepsy, intellectual disability (ID) and schizophrenia. Childhood onset schizophrenia (COS), defined a...
Phenotypic characterization of C57BL/6J mice carrying the Disc1 gene from the 129S6/SvEv strain.
Disruption of disrupted-in-schizophrenia 1 (DISC1), a candidate susceptibility gene for schizophrenia, was first identified in a large Scottish family in which many members suffered from various psych...
BACKGROUND: The Grin1 (glutamate receptor, ionotropic, NMDA1) gene expresses a subunit of N-methyl-D-aspartate (NMDA) receptors that is considered to play an important role in excitatory neurotransmis...
Case report of a patient with schizophrenia and a mutation in the insulin receptor substrate-4 gene.
This report deals with a female patient with schizophrenia who was found to have a mutation in the insulin receptor substrate-4 gene that is located on chromosome Xq22.3. Since this mutation is expect...
Schizotypy is a multidimensional personality construct representing the extension of psychosis-like traits into the general population. Schizotypy has been associated with attenuated expressions of ma...
Treatment delay and pathways to care in early psychosis.
OBJECTIVE: To examine the treatment delay associated with community and inpatient pathways into care for persons experiencing a first episode of psychosis. METHODS: A total of 104 clients entering a s...
Cognitive training in schizophrenia: golden age or wild west?
News Articles
Help at hand for people with schizophrenia
How can healthy people who hear voices help schizophrenics? Finding the answer for this is at the centre of research conducted at the University of Bergen.
Author Bruce Venter Announces the Release of ‘‘Paranoid Schizophrenia: My Label, My Life”
New memoir reveals a success story despite a life-changing diagnosis. EASTLEIGH, England (PRWEB) May 24, 2013 In his new memoir “Paranoid Schizophrenia: My Label, My Life” (published by AuthorHou...
Study finds differences in the brains of patients suffering from psychiatric diseases
Studying the networks of connections in the brains of people affected by schizophrenia, bipolar disease or depression has allowed Dr. Peter Williamson, from Western University, to gain a better unders...
Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Deutsche Bank 38th Annual dbAccess Health Care Conference on Wednesd...
J&J plans filing on more than 10 new drugs by 2017
(Reuters) - Johnson & Johnson said on Thursday it plans to submit more than 10 new products for regulatory approval by 2017, including drugs to treat hepatitis C, immune diseases and schizophrenia, an...
UPDATE 1-J&J plans filing on more than 10 new drugs by 2017
May 23 (Reuters) - Johnson & Johnson said on Thursday it plans to submit more than 10 new products for regulatory approval by 2017, including drugs to treat hepatitis C, immune diseases and schizophre...
Researchers Discover Why Old Schizophrenia Medicine Works on Antibiotic-Resistant Bacteria
In 2008 researchers from the University of Southern Denmark showed that the drug thioridazine, which has previously been used to treat schizophrenia, is also a powerful weapon against antibiotic-resis...
Johnson & Johnson plans on more than 10 drugs filed by 2017
May 23 (Reuters) - Johnson & Johnson said on Thursday that it plans to submit more than 10 new products for regulatory approval by 2017, including drugs to treat hepatitis C, immune diseases, and schi...
Edison Investment - Alexza Pharmaceuticals - Stage set for Adasuve
Alexza’s US marketing deal with Teva for Adasuve (orally-inhaled loxapine) enhances the product’s US sales prospects given Teva’s expertise in the psychiatric and hospital markets....
Networks of neurons in brain are disrupted in psychiatric disease
Studying the networks of connections in the brains of people affected by schizophrenia, bipolar disease or depression has allowed researchers to gain a better understanding of the biological basis of...
Events
None
Companies
Eli Lilly and Company is a leading, innovation-driven corporation committed to developing a growing portfolio of best-in-class and first-in-class pharmaceutical products that help people live longer...
Aestus Therapeutics and Prosidion Ltd.
Aestus Therapeutics, Inc. is a translational medicine company focused on serious neurological diseases. Capitalizing on genomic data analysis to discover novel links between these...
SAGE Therapeutics is a central nervous system (CNS) product focused company building a portfolio of new therapies to meet the growing unmet need in a range of CNS disorders, inclu...
BioLineRx Ltd. and Compugen Ltd.
BioLineRx Ltd. is a publicly-traded biopharmaceutical development company. It is dedicated to building a portfolio of products for unmet medical needs or with advantages over curr...
EnVivo Pharmaceuticals, Inc. and its subsidiaries (âEnVivo Pharmaceuticalsâ or âEnVivoâ) are dedicated to discovering and developing small molecule therapeutic...
Aestus Therapeutics, Inc. is a translational medicine company focused on serious neurological diseases. Capitalizing on genomic data analysis to discover novel links between these...
ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally discovered products designed to eliminate known safety issues associated with well...
NeurOp, Inc. is an Atlanta-based biopharmaceutical company developing new medicines for central nervous system disorders, including depression, neuropathic pain, ischemia (stroke)...
PsychoGenics is a leader in preclinical behavioral neurobiology. The Company applies its behavioral expertise together with advances in robotics, computer vision, and informatics...
Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), o...
Clinical Trials
The purpose of this study is to evaluate the efficacy, safety, and tolerability of two doses (12.5 and 50 mg) of NBI-98854 administered once daily (q.d.) for the treatment of tardive dyski...
1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain
We will conduct a 12-week, randomized open label study, comparing usual care (UC) antipsychotic treatment (aripiprazole, quetiapine, risperidone) with ziprasidone (ZIP) in children and ado...
D-Serine Monotherapy for Schizophrenia
N-methyl-D-aspartate receptor (NMDAR) agonist, added to classical or atypical antipsychotic medication, has reduced negative, depressive, and cognitive symptomatology. We will be investiga...
D-Serine Adjuvant Treatment for Parkinson's Disease
The proposed experiment will evaluate the effects of the NMDA receptor full agonist D-serine (~2g/day) on persistent symptoms of Parkinson's Disease and on antiparkinsonian drugs-induced d...
The purpose of this study is to determine that the efficacy of the sustained release (SR) formulation of quetiapine (Seroquel) is not inferior to the immediate release (IR) formulation....
The purpose of this 6-week study is to determine whether treatment with Seroquel® Sustained Release (SR) is more effective than placebo in the treatment of acute schizophrenia. PLEASE NO...
Janssen - Glucose Regulation/Risp/Olanz
Abnormalities in peripheral glucose regulation and type 2 diabetes can occur more commonly in individuals with schizophrenia than in healthy subjects or in other psychiatric conditions. A...
Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole
This proposal aims to use well-validated methodologies such as dual energy x-ray absorptiometry (DEXA), frequently sampled oral glucose tolerance tests (fsOGTTs), and hyperinsulinemic eugl...
A Research Study Examining the Use of Olanzapine for the Prevention of Migraine
Olanzapine (o-lan-zah-peen) is a medication that has been approved by the Food and Drug Administration (FDA) for the treatment of patients with schizophrenia and/ or bipolar disorder. The...
Olanzapine is an atypical antipsychotic agent indicated for the treatment of schizophrenia and moderate to severe manic episode. Olanzapine is among the many antipsychotic agents associat...
Videos
Inside the World of Childhood Schizophrenia
"20/20" follows three families whose young kids have mental illnesses.
Medical and Biotech [MESH] Definitions
Executive Function
A set of cognitive functions that controls complex, goal-directed thought and behavior. Executive function involves multiple domains, such as CONCEPT FORMATION, goal management, cognitive flexibility, INHIBITION control, and WORKING MEMORY. Impaired executive function is seen in a range of disorders, e.g., SCHIZOPHRENIA; and ADHD.
Theory Of Mind
The ability to attribute mental states (e.g., beliefs, desires, feelings, intentions, thoughts, etc.) to self and to others, allowing an individual to understand and infer behavior on the basis of the mental states. Difference or deficit in theory of mind is associated with ASPERGER SYNDROME; AUTISTIC DISORDER; and SCHIZOPHRENIA, etc.
Schizophrenia
A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
Schizophrenia, Catatonic
A type of schizophrenia characterized by abnormality of motor behavior which may involve particular forms of stupor, rigidity, excitement or inappropriate posture.
Schizophrenia, Childhood
An obsolete concept, historically used for childhood mental disorders thought to be a form of schizophrenia.
